Cabaletta Bio, Inc. Overview
Pro stress-test →Cabaletta Bio is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The company applies its CABA platform to develop T cell therapies to transform the lives of patients with autoimmune diseases by aiming to deliver deep and durable – potentially curative – responses.
Strategic Profile
Pro stress-test →The CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) with CABA-201, a 4-1BB-containing fully human CD19-CAR T as lead candidate, and CAART (chimeric autoantibody receptor T cells) with multiple clinical-stage candidates. The company has initiated enrollment in its first pivotal program in myositis and expects the study could support a biologics license application (BLA) filing next year.
Competitive Landscape
Pro stress-test →Cabaletta competes in the CD19-CAR T space for autoimmunity, a nascent market where competitors include Allogene Therapeutics and Century Therapeutics pursuing similar approaches. Building on established success of T cell therapies in cancer and recent compelling clinical data on CD19-CAR T in autoimmunity, Cabaletta is developing CARTA to address a broad range of autoimmune diseases. Differentiation lies in disease specificity (autoimmunity vs. oncology heritage) and multi-indication platform scope.
Industry Context
Cabaletta Bio, Inc. operates in Biotechnology - Cell & Gene Therapy.
Key facts
Founded: 2017 · Headquarters: Philadelphia, PA